Principal Investigator
Gretel Terrero
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20230982
Clinical Trial Summary
Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Stomach and Esophageal Cancer
Contact Information
Phone Number
305-243-2647